Ocular Pharmacodynamics of Intravitreal Faricimab in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema
A popPKPD analysis suggested that sustained suppression of ocular Ang-2 contributes to faricimab's extended durability, observed in clinical trials.
Authors
- Katrijn Bogman (ORCID: https://orcid.org/0000-0003-2191-4461)
- Ekaterina Gibiansky
- Cheikh Diack (ORCID: https://orcid.org/0000-0002-6320-7522)
- Félix Jaminion
- Leonid Gibiansky (ORCID: https://orcid.org/0000-0001-6005-7760)
- Ivo Stoilov
- Robert L. Avery
- Valérie Cosson
- Chui Ming Gemmy Cheung (ORCID: https://orcid.org/0000-0003-3358-3516)
- Karl G. Csaky (ORCID: https://orcid.org/0000-0002-5466-8829)
- Denise Sickert
Institutions
- Roche (Switzerland) (CH)
- National University of Singapore (SG)
- Singapore National Eye Center (SG)
- California Retina Consultants (US)
- Singapore Eye Research Institute (SG)
- Duke-NUS Medical School (SG)
- Retina Foundation of the Southwest (US)
Publication Details
- Journal
- Translational Vision Science & Technology
- Published
- 2024-11-13
- DOI
- https://doi.org/10.1167/tvst.13.11.13
- Citations
- 11
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 5.93
Funders
- Amgen
- Alexion Pharmaceuticals
- F. Hoffmann-La Roche
- Regeneron Pharmaceuticals
- Alimera Sciences
- Cardinal Health
- NGM Biopharmaceuticals
- Apellis Pharmaceuticals
- Aldeyra Therapeutics
- Coherus Biosciences
- Santen
- Astellas Pharma
- Heidelberg Engineering
- Genentech
- Samsung
- Allergan
- Novartis Pharma